2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
22
Lymphoma, Non-Hodgkin
6
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
6
Lymphoma
5
Vomiting
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Nausea
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
HIV Infections
1
Interventions
Rituximab
161
Cyclophosphamide
142
fludarabine phosphate
89
Peripheral Blood Stem Cell Transplantation
81
Filgrastim
59
Mycophenolic Acid
58
Whole-Body Irradiation
53
Cyclosporine
53
Radiotherapy
52
Lenalidomide
47
Busulfan
45
Tacrolimus
44
Etoposide
43
Antilymphocyte Serum
41
Melphalan
37
Methotrexate
31
fludarabine
30
Bortezomib
30
Prednisone
28
Bendamustine Hydrochloride
28
Cytarabine
24
Cord Blood Stem Cell Transplantation
23
obinutuzumab
22
Vincristine
22
Methylprednisolone
21
Flow Cytometry
21
ibrutinib
19
venetoclax
17
sargramostim
17
Granulocyte Colony-Stimulating Factor
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
R-CHOP protocol
×
Clear all
NCT04542824
2026-05-05
EPCOREâ„¢ NHL-3
Genmab
Phase 1/2
Active not recruiting
78 enrolled